These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8549030)

  • 1. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
    Peck R; Wiggs R; Callaghan J; Wootton R; Crome P; Fraser I; Frick L; Posner J
    Clin Pharmacol Ther; 1996 Jan; 59(1):22-31. PubMed ID: 8549030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
    Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
    Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles.
    Peck RW; Crome P; Wood MJ; McKendrick MW; Bannister B; Mandal BK; Crooks RJ
    J Antimicrob Chemother; 1996 Mar; 37(3):583-97. PubMed ID: 9182115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment.
    Fillastre JP; Godin M; Legallicier B; Chretien P; Bidault R; Gillotin C; Wooton R; Posner J; Peck RW
    J Antimicrob Chemother; 1996 May; 37(5):965-74. PubMed ID: 8737146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
    Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)-uracil and a metabolite, 5-propynyluracil, in plasma using ASTED (automated sequential trace enrichment of dialysates) combined, on-line, with high-performance liquid chromatography.
    Buick AR; Sheung CT
    J Chromatogr; 1993 Jul; 617(1):65-70. PubMed ID: 8376539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent.
    Peck RW; Wootton R; Lee DR; Jackson SH; Posner J
    Br J Clin Pharmacol; 1995 Feb; 39(2):143-9. PubMed ID: 7742152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers.
    Peck RW; Weatherley BC; Wootton R; Crome P; Holdich TA; Posner J
    Antimicrob Agents Chemother; 1995 Jan; 39(1):20-7. PubMed ID: 7695306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes.
    Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA
    Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.
    Diasio RB
    Br J Clin Pharmacol; 1998 Jul; 46(1):1-4. PubMed ID: 9690942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
    Naguib FN; Hao SN; el Kouni MH
    Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
    Watabe T; Ogura K; Nishiyama T
    Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.